wave graphic mobile

The Minaris Advanced Therapies Story

A Global Leader in Cell and Gene Therapy CDMO
and Contract Testing Services

Minaris Advanced Therapies has over 25 years of experience in developing, manufacturing and testing therapies as a specialized CDMO focusing on cell and gene therapy. We support innovators from preclinical development through commercial production. Our technical expertise, global infrastructure and end-to-end services ensure consistent delivery, efficient tech transfer and scalable manufacturing solutions.

We are committed to helping clients advance their programs and increase patient access worldwide.

Work with a partner that delivers proven results across every phase of development, manufacturing and quality control.

Connect With Our Experts

A LEGACY OF INNOVATION

From Pioneers to Global Powerhouse

Minaris Advanced Therapies was formed by combining two highly experienced organizations.

The first organization was Minaris Regenerative Medicine, which had been the cell and gene therapy division of Hitachi Chemical and had extensive manufacturing experience in the United States, Europe and Japan.

The second organization was Advanced Therapies, LLC, which had been the Advanced Therapies business unit of WuXi AppTec, focused on viral vector and cell therapy manufacturing, GMP analytical and biosafety testing and analytical development services.

Together, these entities were combined to create Minaris Advanced Therapies, a global CDMO with the scale, technology and expertise to assist therapy developers at every stage, from early-phase biotechs to commercial biopharma.

Supported by Altaris Capital, this merger combines decades of operational, scientific and commercial excellence into a single, purpose-built global CDMO aimed at accelerating advanced therapy development and expanding patient access worldwide.

Read the Press Release

COMPANY HISTORY:

Milestones in Minaris’ Global Growth

Minaris Advanced Therapies brings together two pioneers in cell and gene therapy to form a single, globally integrated CDMO and advanced testing organization. Our roots span clinical diagnostics, viral vector innovation and some of the earliest commercial cell therapy manufacturing programs in the world.

2025 and Beyond

  • Minaris operates as a unified, global CDMO and CTO delivering end-to-end advanced therapy solutions across North America, Europe and Asia.
  • With integrated processes, accelerated tech transfers and ongoing investment in innovation, Minaris helps enable access to life-changing therapies worldwide.

2025

  • Altaris Capital Partners acquires Minaris Regenerative Medicine and WuXi Advanced Therapies, combining the companies to launch Minaris Advanced Therapies.

2023–2024

  • Minaris supports multiple commercial launches globally, investing in expanded manufacturing and testing capacity.

2021

  • WuXi Advanced Therapies acquires OXGENE, adding discovery and R&D services to its CGT portfolio.

2018

  • WuXi AppTec spins out WuXi Advanced Therapies, creating a standalone CGT manufacturing and testing business.
  • Signs a commercial agreement with Nohla Therapeutics.
  • Hitachi Chemicals opens Yokohama’s dedicated GMP facility to support commercial production in Japan.

2015–2016

  • Two new GMP manufacturing sites are established in Philadelphia, supporting cell and gene therapy and viral vector production at clinical and commercial scale.

2014

  • The Philadelphia facility expands to offer integrated advanced therapy testing and manufacturing.

2011

  • Hitachi Chemical acquires PCT, launching Minaris Regenerative Medicine and expanding its presence into Europe and Japan.

2008

  • WuXi PharmaTech acquires AppTec to form WuXi AppTec.
  • Philadelphia operations continue biopharmaceutical testing and cell bank manufacturing.

2004

  • Philadelphia manufactures the first GMP cell therapy lot, marking a significant milestone in U.S.-based CGT development.

2001

  • WuXi PharmaTech was founded in Shanghai, China, by Dr. Ge Li.
  • AppTec Laboratory Services is formed with sites in St. Paul, Atlanta and Philadelphia.

1999

  • Progenitor Cell Therapy (PCT) is established in the United States as one of the first CDMOs dedicated exclusively to supporting clinical-stage cell therapies.

1996–1998

  • ViroMed acquires Axios and Quality Biotech. A new testing site is opened in St. Paul, MN, expanding the company’s viral vector expertise.

1988

  • Quality Biotech opens in Camden, NJ, establishing biopharmaceutical testing capabilities near what would become a central U.S. hub for cell and gene therapy.

1982

  • ViroMed Laboratories was founded in Minneapolis, MN, offering clinical diagnostics with a focus on viral vectors.

Proven Commercial Manufacturing Experience

Minaris has a strong record of delivering commercial manufacturing success. We have supported nine commercial products and continue to support ongoing commercial programs today.

Our facilities are approved for commercial manufacturing by the FDA, EMA and PMDA, and we have proven commercial experience in the US, Europe and Japan. In addition to our commercial manufacturing experience, we currently provide testing services for 27 commercial products.

Ready to scale globally with confidence?

Connect with our Team

MINARIS ADVANCED TESTING

Supporting the Broader Biologics Industry

In addition to supporting our CDMO clients, Minaris Advanced Testing offers standalone services for mAbs, vaccines and cell and gene therapy providers who are manufacturing on their own or using another CDMO.

Our 140,000 sq. ft. dedicated testing facility and team in Philadelphia offers the following:

  • Analytical development
  • Cell banking
  • Cell line characterization
  • Lot release
  • Potency testing
  • Stability studies
  • Viral clearance

Whether integrated into our manufacturing programs or offered independently, our testing services reduce risk, cost and turnaround time.

Access Proven Testing Expertise

Enabling Access Through Innovation

At Minaris Advanced Therapies, access to advanced therapies should not be limited by cost, complexity or geography. Our vision is built on five strategic pillars:

The patient is waiting

We reduce vein-to-vein time to accelerate delivery to patients.

Right first time

Quality is a leadership priority and core commitment we make to our partners, patients and ourselves.

Increase patient access

We are actively working to help the industry reduce batch costs by up to 70%.

Innovate to enable

We utilize closed systems, automated workflows, and platform-based approaches to enhance scalability and mitigate manufacturing risk.

One company

We deliver harmonized operations and a consistent customer experience across all Minaris Advanced Therapies facilities.

Integrated Services From Development to Delivery

Minaris Advanced Therapies provides a comprehensive range of cell and gene therapy CDMO and testing services covering the entire product lifecycle. Our in-house testing division, Minaris Advanced Testing, offers faster turnaround times, reduces dependence on third-party testing and ensures data integrity across programs.

Partnering to Transform Cell and Gene Therapy

Minaris Advanced Therapies isn’t just a manufacturing and testing partner. We lead the advancement of next-generation cell and gene therapies. We share industry knowledge, support scalable tech and challenge outdated methods to deliver therapies globally.

Whether launching a clinical program or preparing for commercialization, we offer expertise, global reach and commitment to support your success.

Connect to Experts

Explore All
Minaris Services

Contact Us

Minaris Advanced Therapies is dedicated to helping innovators in cell and gene therapy succeed. Whether you are in early-stage development or preparing for commercial launch, our end-to-end expertise, global reach and commitment to quality make us the ideal partner for cell and gene therapy manufacturing and GMP biosafety and analytical testing of all biologics.

Get in Touch